Study protocol for a Randomised controlled trial of EArly transjugular intrahepatiC porTosystemic stent-shunt in Acute Variceal Bleeding (REACT-AVB trial).

CIRRHOSIS GASTROINTESTINAL BLEEDING OESOPHAGEAL VARICES PORTAL HYPERTENSION STENTS

Journal

BMJ open gastroenterology
ISSN: 2054-4774
Titre abrégé: BMJ Open Gastroenterol
Pays: England
ID NLM: 101660690

Informations de publication

Date de publication:
22 Mar 2024
Historique:
received: 02 12 2023
accepted: 16 02 2024
medline: 23 3 2024
pubmed: 23 3 2024
entrez: 22 3 2024
Statut: epublish

Résumé

In liver cirrhosis, acute variceal bleeding (AVB) is associated with a 1-year mortality rate of up to 40%. Data on early or pre-emptive transjugular intrahepatic portosystemic stent-shunt (TIPSS) in AVB is inconclusive and may not reflect current management strategies. Randomised controlled trial of EArly transjugular intrahepatiC porTosystemic stent-shunt in AVB (REACT-AVB) aims to investigate the clinical and cost-effectiveness of early TIPSS in patients with cirrhosis and AVB after initial bleeding control. REACT-AVB is a multicentre, randomised controlled, open-label, superiority, two-arm, parallel-group trial with an internal pilot. The two interventions allocated randomly 1:1 are early TIPSS within 4 days of diagnostic endoscopy or secondary prophylaxis with endoscopic therapy in combination with non-selective beta blockers. Patients aged ≥18 years with cirrhosis and Child-Pugh Score 7-13 presenting with AVB with endoscopic haemostasis are eligible for inclusion. The primary outcome is transplant-free survival at 1 year post randomisation. Secondary endpoints include transplant-free survival at 6 weeks, rebleeding, serious adverse events, other complications of cirrhosis, Child-Pugh and Model For End-Stage Liver Disease (MELD) scores at 6 and 12 months, health-related quality of life, use of healthcare resources, cost-effectiveness and use of cross-over therapies. The sample size is 294 patients over a 4-year recruitment period, across 30 hospitals in the UK. Research ethics committee of National Health Service has approved REACT-AVB (reference number: 23/WM/0085). The results will be submitted for publication in a peer-reviewed journal. A lay summary will also be emailed or posted to participants before publication. ISRCTN85274829; protocol version 3.0, 1 July 2023.

Identifiants

pubmed: 38519049
pii: bmjgast-2023-001314
doi: 10.1136/bmjgast-2023-001314
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

Matthew Armstrong (M)
Andrew King (A)
Faisal Khan (F)
David Patch (D)
Evangelia Fatourou (E)
Jayshri Shah (J)
Naaventhan Palaniyappan (N)
Imran Patanwala (I)
Jeremy Cobbold (J)
Richard J Aspinall (RJ)
Steven Masson (S)
Teik Choon See (TC)
Edward Britton (E)
Syed Alam (S)
Janisha Patel (J)
Victoria J Appleby (VJ)
Robert Driver (R)
Laura Harrison (L)
Ameet Dhar (A)
James Maurice (J)
Jude Morris (J)
Adrian Stanley (A)
Peter Hayes (P)
Joanna Leithead (J)
Ruairí Lynch (R)
Tom Pembroke (T)
Jagadish Nagaraj (J)
Fidan Yousuf (F)
Roger McCorry (R)

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Dhiraj Tripathi (D)

Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, Birmingham, UK d.tripathi@bham.ac.uk.
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

David Patch (D)

Hepatology and Liver Transplantation, Royal Free Hampstead NHS Trust, London, UK.

Homoyon Mehrzad (H)

Interventional Radiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, Birmingham, UK.

Dominic Yu (D)

Department of Radiology, Royal Free London NHS Foundation Trust, London, UK.

Richard J Aspinall (RJ)

Gastroenterology and Hepatology, Portsmouth Hospitals NHS Trust, Portsmouth, UK.

Matthew J Armstrong (MJ)

Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, Birmingham, UK.

Adrian Stanley (A)

GI Unit, Glasgow Royal Infirmary, Glasgow, Glasgow, UK.

Hamish Ireland (H)

Department of Radiology, Royal Infirmary of Edinburgh, Edinburgh, UK.

Simon Travis (S)

Department of Radiology, Nottingham University Hospitals NHS Trust, Nottingham, UK.

Peter Hayes (P)

Hepatology, Royal Infirmary of Edinburgh, Edinburgh, UK.

Mandy Lomax (M)

Walton-on-Thames, Walton-on-Thames, UK.

Nicholas Roslund (N)

London, London, UK.

Emily Lam (E)

GI and Liver PPI Group, University Hospitals Birmingham NHS Foundation Trust, Birmingham, Birmingham, UK.

Gemma Slinn (G)

Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, West Midlands, UK.

Sue Jowett (S)

Institute of Applied Health Research, University of Birmingham, Birmingham, West Midlands, UK.

Catherine Moakes (C)

Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, West Midlands, UK.

Alisha Maher (A)

Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, West Midlands, UK.

Elizabeth Brettell (E)

Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, West Midlands, UK.

Sukhwant Sehmi (S)

Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, West Midlands, UK.

Classifications MeSH